Target intelligence / Profile preview

RNA-induced silencing complex (RISC) / Argonaute-2 (Ago2) machinery (RISC/Ago2)

Target
RISC/Ago2
Molecular classification
Enzyme, Other
01

Overview

The RNA-induced silencing complex (RISC) / Argonaute-2 (Ago2) machinery is a multi-protein ribonucleoprotein complex that serves as the core effector of the RNA interference (RNAi) pathway. At its catalytic center is Argonaute-2 (Ago2), an endonuclease (slicer) that binds small regulatory RNAs, such as microRNAs (miRNAs) and small interfering RNAs (siRNAs), to guide post-transcriptional gene silencing. Upon loading of a double-stranded RNA duplex, the passenger strand is discarded, and the remaining guide strand directs the complex to complementary target messenger RNAs (mRNAs). Perfect complementarity triggers Ago2-mediated endonucleolytic cleavage of the target mRNA, whereas partial complementarity leads to translational repression and mRNA decay. This machinery is highly exploited by therapeutic siRNAs to selectively silence disease-causing genes. Approved siRNA drugs, such as patisiran, inclisiran, and fitusiran, utilize this endogenous pathway to treat a variety of conditions, including amyloidosis, hypercholesterolemia, and hemophilia. However, therapeutic challenges include avoiding off-target effects from partial sequence matches and preventing the saturation of the endogenous RISC machinery, which could disrupt essential physiological miRNA pathways.

Other names
RNA-induced silencing complexRISCArgonaute-2Ago2RISC/Ago2 complexRISC loading complexRLCArgonaute RISC catalytic component 2Eukaryotic translation initiation factor 2C 2eIF-2C 2
02

Mechanism of action

The RISC/Ago2 machinery is utilized by small interfering RNAs (siRNAs) to achieve sequence-specific gene silencing. Upon cellular uptake, the double-stranded siRNA is loaded into the RISC/Ago2 complex. The passenger strand is cleaved and discarded, while the guide strand is retained by Argonaute-2 (Ago2). The guide strand then directs the active RISC to complementary target mRNA transcripts via Watson-Crick base pairing, where the endonuclease (slicer) activity of Ago2 cleaves the target mRNA, leading to its degradation and subsequent inhibition of translation.

03

Biological functions

Other
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseInfectionOther
05

Safety considerations

Off-target gene silencing due to partial complementarity of the siRNA guide or passenger strand (seed-mediated off-target effects)Saturation of the endogenous RISC/Ago2 machinery, which can disrupt natural microRNA (miRNA) pathways and compromise cellular homeostasisHepatotoxicity and transient elevations in liver transaminasesInjection site reactionsInnate immune activation and cytokine release triggered by double-stranded RNA recognition by toll-like receptors (TLRs)Thrombotic events or excessive blood clotting (specifically for antithrombin-targeting agents like fitusiran)
06

Interacting drugs

12 more in the full profile.

07

Biomarkers

Transthyretin (TTR) levelsAminolevulinic acid (ALA) levelsPorphobilinogen (PBG) levelsUrinary oxalate levelsLow-density lipoprotein cholesterol (LDL-C) levelsProprotein convertase subtilisin/kexin type 9 (PCSK9) levelsAntithrombin (AT) activityApolipoprotein C-III (ApoC3) levelsTriglyceride levels

Beyond the preview

Go deeper on RNA-induced silencing complex (RISC) / Argonaute-2 (Ago2) machinery (RISC/Ago2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA-induced silencing complex (RISC) / Argonaute-2 (Ago2) machinery (RISC/Ago2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call